StreetInsider.com News Articles

Biodesix (BDSX) PT Raised to $40 at TD Cowen

Tue, 13 Oct 2026 09:32:02 -0400

TD Cowen analyst Dan Brennan raised the price target on Biodesix (NASDAQ: BDSX) to $40.00 (from $30.00) while maintaining a rating.

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Tue, 13 Oct 2026 06:00:00 -0400

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

LOUISVILLE, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced multiple presentations at CHEST 2026 highlighting how Nodify Lung testing is being incorporated into real-world lung nodule management. The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects patient adherence to follow-up, and optimizes the use of imaging and other diagnostic procedures.

New analyses from the CLARIFY study,

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

Tue, 13 Oct 2026 06:00:00 -0400

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing

New analyses from the CLARIFY study,

Form 4 BIODESIX INC For: Sep 30 Filed by: PATIENCE JOHN

Fri, 02 Oct 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20261002/27142367.html

Biodesix (BDSX) PT Raised to $38 at H.C. Wainwright

Mon, 28 Sep 2026 06:55:56 -0400

H.C. Wainwright analyst Yi Chen raised the price target on Biodesix (NASDAQ: BDSX) to $38.00 (from $27.00) while maintaining a Buy rating.

Biodesix (BDSX) PT Raised to $38 at H.C. Wainwright

Fri, 25 Sep 2026 12:53:45 -0400

H.C. Wainwright analyst Yi Chen raised the price target on Biodesix (NASDAQ: BDSX) to $38.00 while maintaining a Buy rating.

Biodesix advances two MRD monitoring programs with Bio-Rad and Thermo Fisher

Thu, 24 Sep 2026 06:00:48 -0400

Biodesix, Inc. (Nasdaq: BDSX) announced progress in two collaborative programs for Molecular Residual Disease (MRD) monitoring, one tumor-informed and one tumor-naïve, both designed to detect circulating tumor DNA (ctDNA) in blood to assess whether cancer remains or is returning after treatment.

The tumor-informed solution, developed through a multi-year collaboration with Bio-Rad Laboratories, uses Biodesix's Diagnostic Cortex bioinformatics platform to identify genomic changes unique to a patient's tumor. Bio-Rad's Droplet Digital PCR technology then tracks those changes in blood, detecting ctDNA below 1 part per million of total DNA in a blood sample.

The tumor-naïve solution is part of a newly launched program

Biodesix advances two MRD monitoring programs with Bio-Rad and Thermo Fisher

Thu, 24 Sep 2026 06:00:48 -0400

The tumor-naïve solution is part of a newly launched program

Biodesix advances two MRD monitoring programs with Bio-Rad and Thermo Fisher

Thu, 24 Sep 2026 06:00:48 -0400

The tumor-naïve solution is part of a newly launched program

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Thu, 24 Sep 2026 06:00:00 -0400

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise

LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tumor DNA (ctDNA), the tumor DNA that a cancer sheds into the blood, to assess whether disease remains or is returning after treatment. The tumor-informed solution is the result of a multi-year collaboration with Bio-Rad Laboratories. The tumor-naïve

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Thu, 24 Sep 2026 06:00:00 -0400

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Mon, 14 Sep 2026 16:01:00 -0400

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

LOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that Brianna Phillips, Vice President of Quality and Regulatory Affairs at Biodesix, will be presenting at the upcoming Regulatory Affairs Professionals Society (RAPS) and Society of Clinical Research Associates (SOCRA) Annual Meetings.

These important professional society meetings put a spotlight on the material influence and need for Quality Affairs and Regulatory Affairs (QA/RA) expertise in the medical diagnostics

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Mon, 14 Sep 2026 16:01:00 -0400

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

These important professional society meetings put a spotlight on the material influence and need for Quality Affairs and Regulatory Affairs (QA/RA) expertise in the medical diagnostics

Biodesix to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 06:00:00 -0400

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:

Lake Street Capital Markets’ 10^th Annual Best Ideas Growth (BIG10) Conference
1x1 meetings only
Date: Thursday, September 10
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
1x1 meetings only
Date: Tuesday, September 15
Location: New York

5^th Annual Roth Healthcare Opportunities Conference
Panel and 1x1 meetings
Panel Title: The Rise of MRD Monitoring in Solid Tumors, and

Biodesix to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 06:00:00 -0400

Lake Street Capital Markets’ 10^th Annual Best Ideas Growth (BIG10) Conference
1x1 meetings only
Date: Thursday, September 10
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
1x1 meetings only
Date: Tuesday, September 15
Location: New York

5^th Annual Roth Healthcare Opportunities Conference
Panel and 1x1 meetings
Panel Title: The Rise of MRD Monitoring in Solid Tumors, and

Form 4 BIODESIX INC For: Aug 12 Filed by: SCHULER JACK W

Thu, 13 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260813/26922818.html

Form 4 BIODESIX INC For: Aug 12 Filed by: SCHULER JACK W

Thu, 13 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260813/26922818.html

Form 4 BIODESIX INC For: Aug 10 Filed by: SCHULER JACK W

Wed, 12 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260812/26914568.html

Form 4 BIODESIX INC For: Aug 10 Filed by: SCHULER JACK W

Wed, 12 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260812/26914568.html

Biodesix (BDSX) PT Raised to $35 at Canaccord

Mon, 10 Aug 2026 05:48:43 -0400

Canaccord analyst Kyle Mikson raised the price target on Biodesix (NASDAQ: BDSX) to $35.00 (from $27.00) while maintaining a Buy rating.

The analyst comments "We reiterate our BUY rating on Biodesix (BDSX) shares and increase our price target to $35 from $27. Our price target increase is driven by higher revenue in 2026 and beyond in our 10-year DCF model. After the market close on Wednesday, August 5, the company reported 2Q26 results that were ahead of our estimates and FactSet consensus. Biodesix delivered another strong quarter driven by strength in Nodify test volume, improved average revenue per test and traction

Biodesix (BDSX) PT Raised to $35 at Canaccord

Mon, 10 Aug 2026 05:48:43 -0400

Canaccord analyst Kyle Mikson raised the price target on Biodesix (NASDAQ: BDSX) to $35.00 (from $27.00) while maintaining a Buy rating.

Biodesix Inc. (BDSX) Tops Q2 EPS by 19c

Wed, 05 Aug 2026 18:01:55 -0400

Biodesix Inc. (NASDAQ: BDSX) reported Q2 EPS of ($0.71), $0.19 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $25.96 million.

For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.

Form 10-Q BIODESIX INC For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873996.html

Form 10-Q BIODESIX INC For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873996.html

Form 8-K BIODESIX INC For: Aug 05

Wed, 05 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260805/26873668.html